Ventyx Biosciences reported Phase 2 data showing oral NLRP3 inhibitor VTX3232 produced rapid and large reductions in high-sensitivity C-reactive protein (hsCRP), with a 78% decline versus placebo over 12 weeks and an almost 80% drop in one-week analyses. The trial enrolled patients with obesity and cardiovascular risk factors; safety and tolerability endpoints were met. The biomarker and secondary signals for liver inflammation and lipids prompted investor interest and a sharp jump in Ventyx’s share price, and the company said the results could support partnering discussions aimed at cardiovascular indications. Ventyx plans to further explore NLRP3 targeting across cardiometabolic and neurologic indications, leveraging oral small-molecule delivery to broaden clinical reach.